Ozempic (semaglutide), a GLP-1 agonist approved for Type 2 diabetes management and prescribed off-label for weight loss, is injected once a week
Many of these new substances appear so fast and with little efficacy support in the literature making it difficult for anti-doping authorities to properly evaluate and consider if they are a problem from the standpoint of performance enhancement
If you're triggered, take a break, reach out to me in the portal, and if it would help I can refer you to one of our licensed practitioners for a session or two to debrief
Karatas, H., Eun Jung, J., Lo, E
Novo Nordisk already successfully expanded use of Wegovy for cardiovascular benefits, opening the door for greater insurance coverage, as well as the lucrative Medicare market
Introduction PC remains a highly fatal malignancy and is the fourth leading cause of cancer-related mortality in both sexes in the United States (Rahib et al., 2014